Investigating the Nucleic Acid Interactions of Histone-Derived Antimicrobial Peptides by Sim, Sukin et al.
Wellesley College
Wellesley College Digital Scholarship and Archive
Faculty Research and Scholarship
1-28-2017








See next page for additional authors
Follow this and additional works at: https://repository.wellesley.edu/scholarship
Version: Post-print
This Article is brought to you for free and open access by Wellesley College Digital Scholarship and Archive. It has been accepted for inclusion in
Faculty Research and Scholarship by an authorized administrator of Wellesley College Digital Scholarship and Archive. For more information, please
contact ir@wellesley.edu.
Recommended Citation
Sim, S. , Wang, P. , Beyer, B. N., Cutrona, K. J., Radhakrishnan, M. L. and Elmore, D. E. (2017), Investigating the nucleic acid
interactions of histone‐derived antimicrobial peptides. FEBS Lett, 591: 706-717. doi:10.1002/1873-3468.12574
Authors
Sukin Sim, Penny Wang, Brittany N. Beyer, Kara J. Cutrona, Mala L. Radhakrishnan, and Donald E. Elmore
This article is available at Wellesley College Digital Scholarship and Archive: https://repository.wellesley.edu/scholarship/179
    Sim et al., 1 
Title: 
 





Sukin Sim1, Penny Wang1, Brittany N. Beyer1, Kara J. Cutrona1, Mala L. Radhakrishnan1,2 and 
Donald E. Elmore*1,2 
 
Department of Chemistry1 and Biochemistry Program2 
 
*To whom correspondence should be addressed: 
Donald E. Elmore 
Department of Chemistry and Biochemistry Program 
Wellesley College 
106 Central St. 
Wellesley, MA  02481 
Phone: +1 781-283-3171 
Fax:  +1 781-283-3642 





While many antimicrobial peptides (AMPs) disrupt bacterial membranes, some translocate into 
bacteria and interfere with intracellular processes. Buforin II and DesHDAP1 are thought to kill 
bacteria by interacting with nucleic acids. Molecular modeling and experimental measurements 
were used to show that neither nucleic acid binding peptide selectively binds DNA sequences. 
Simulations and experiments also showed that changing lysines to arginines enhances DNA 
binding, suggesting that including additional guanidinium groups is a potential strategy to 
engineer more potent AMPs. Moreover, the lack of binding specificity may make it more 








AMP, antimicrobial peptide; HDAP, histone-derived antimicrobial peptide; BF2, buforin II; MD, 
molecular dynamics; LINCS, linear constraint solver; FID, fluorescent intercalator displacement 
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Introduction 
 
Growing medical concern of drug resistance has prompted a need to develop alternatives to 
conventional antibiotics [1]. Antimicrobial peptides (AMPs), which are naturally occurring in 
numerous living organisms, are active against a wide range of bacteria and other pathogens and 
therefore show potential as a class of such alternatives [2-4]. While many AMPs kill bacteria 
through membrane permeabilization, a smaller subset of AMPs is believed to inhibit bacterial 
growth by interfering with essential intracellular functions [5, 6]. Buforin II (BF2) and 
DesHDAP1 are two AMPs that share this lesser studied mechanism, with both hypothesized to 
bind nucleic acid as part of their mechanism of action [7-9], although the peptides could 
potentially have other intracellular targets or cause more minor membrane damage that is not 
observed in common assays but still harms bacteria.  
 
BF2 is a 21-amino acid long peptide derived from a naturally occurring peptide in Bufo bufo 
gargarizans [10], and DesHDAP1 [11] is a 20-amino acid long designed peptide based on the 
crystal structure of histone H2A. Previous studies have shown the activity of BF2 and 
DesHDAP1 against several bacterial strains [8, 10-14]. Because each peptide shares its entire 
sequence with a portion of a histone core subunit, both are histone-derived antimicrobial peptides 
(HDAPs). While BF2’s and DesHDAP1’s modes of action involve nucleic acid binding, this 
mechanism is certainly not unique to these two HDAPs [5, 6, 15-19]. For example, some 
puroindoline derived peptides were shown to inhibit macromolecular synthesis via binding DNA 
[20], whereas pseudin-2, an AMP derived from skin of the South American frog Pseudis 
paradoxa, did so via binding RNA [21]. In other studies, a cathelicidin derived peptide appeared 
to bind DNA and decrease replication of a plasmid containing an antimicrobial resistance gene 
[22], and piscidins can cause condensation of DNA in addition to their membrane effects [23]. 
With several peptides and peptidomimetics binding nucleic acids as part of their modes of 
antimicrobial activity, a better understanding of such peptide-nucleic acid binding could 
contribute to engineering of similar AMPs with improved activity.  
 
While nucleic acid binding appears to play a role in the mechanism of these peptides, researchers 
have not considered whether peptides target particular base sequences or have less specificity in 
their binding. Past studies by our lab investigated nucleic acid binding of BF2 using a 
combination of experimental DNA binding assays and molecular dynamics (MD) simulations 
[9]. Subsequently, DesHDAP1, a peptide thought to share a similar mechanism of action as BF2, 
was designed and subjected to identical MD simulation modeling [11]. Although the structural 
models of BF2 and DesHDAP1 bound to DNA in these previous papers implied that the peptides 
likely had little nucleic acid binding specificity, only a single, relatively short (10 ns) MD 
simulation was reported for each peptide and any potential specificity was not considered 
experimentally.  
Understanding any binding selectivity is central to design efforts aimed at developing more 
potent HDAPs. To this end, this current study characterizes the DNA binding of both BF2 and 
DesHDAP1 using multiple MD simulations, electrostatic analyses and experimental nucleic acid 
binding experiments with different repeating DNA sequences. Together, these results show a 
lack of sequence specificity in both of these peptides and emphasize the importance in 
peptide•phosphate interactions in DNA binding. Interestingly, our simulations of BF2 and 
DesHDAP1 also noted that arginine residues played a more significant role than lysine in 
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mediating phosphate interactions. Thus, we also performed additional simulations and 
experimental studies to confirm that increased arginine composition does increase the DNA 
binding of these peptides. In fact, recent studies have shown that BF2 and DesHDAP1 variants 
containing increased arginine versus lysine composition have greater antimicrobial activity [24]. 
While this was attributed to enhanced membrane interactions, the data presented here implies 
that increased DNA interactions may also have played a role. 
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Materials and Methods 
 
Molecular Modeling and MD Simulations 
 
The initial models of BF2 and DesHDAP1 bound to DNA were extracted from the histone core 
particle crystal structure (1AOI) [25] as in previous work [9, 11]. These models incorporated the 
section of the protein with an identical sequence as the peptide along with an adjacent section of 
DNA (21 base pairs with BF2 and 20 base pairs with DesHDAP1). All modeling and 
experiments of BF2 included the F10W mutation. The BF2-DNA and DesHDAP1-DNA 
complexes were refined using MD simulations in Gromacs 4.5.5 [26] with the AMBER03 force 
field [27]. For all simulations, TIP4P-Ew waters were used for BF2 and DesHDAP1, with Na+ 
and Cl- added to neutralize overall charges and provide an additional salt concentration of 100 
mM. Arginine and lysine residues and the N- and C- termini were ionized, while the single His 
side chain was left uncharged in the HID tautomer. Systems were subjected to 100 steps of 
steepest descents minimization and heated to 300 K over 20 ps. Each trajectory was extended to 
a total length of 50 ns at constant temperature (300 K) and isotropic constant pressure (1 bar). 
Simulations used a time step of 2 fs and long-range electrostatics longer than the 10 Å cutoff 
calculated using PME [28]. Bonds to hydrogens were constrained using LINCS [29]. For each 
peptide bound to DNA, five simulations with identical initial structures were run and analyzed. 
MD analyses were performed using tools in the Gromacs package.  
 
 
Energetic analyses of simulation structures 
 
Continuum electrostatic calculations 
 
Continuum electrostatic calculations were performed by solving the linearized Poisson 
Boltzmann Equation with a single-grid red-black successive over-relaxation finite-difference 
solver (M. D. Altman and B. Tidor, unpublished; D. F. Green, E. Kangas, Z. S. Hendsch and B. 
Tidor, Technology Licensing Office, Massachusetts Institute of Technology) [30] for MD 
snapshots taken every ns from 40 to 50 ns. A dielectric constant of 4 was used for all peptide and 
DNA atoms, while the solvent was modeled using a dielectric constant of 80. Bondi radii [31], 
which have been shown to be reasonable for continuum electrostatics calculations [32, 33], were 
used for each atom along with AMBER03 charges. A probe radius of 1.4 Å was used for 
defining the surfaces of these dielectric boundaries. Potentials were solved on a 315×315×315 
grid. A two-tiered focusing procedure was used, with the peptide-DNA complex occupying 23% 
and 92% of the grid, yielding a grid spacing of roughly 3.5 grids/Å at the higher focusing. Zero-
radius and uncharged dummy atoms were placed at identical minimum and maximum points of 
every calculation for equal grid resolution. The ionic strength was set to 100 mM. Total 
electrostatic binding free energies were obtained by summing the desolvation penalties for each 
binding partner (in other words, desolvating the spatial cavities of the binding partners) and the 
solvent-screened interactions between the two partners. The penalty terms were obtained by 
multiplying one-half the potential differences due to charges on a given binding partner by its 
charges. Interaction terms were calculated multiplying bound-state potentials due to charges on a 
binding partner by charges on the other partner [34].  
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Component analyses 
 
To quantify the contributions of selected portions of a binding partner on the overall electrostatic 
binding free energy, atomic charges of these portions were set to zero followed by a re-
calculation of the binding free energy. The contribution of that portion, or the effect of zeroing 
out the charges of the portion, was reflected by the change in the electrostatic binding free 
energy, ΔΔG, obtained by subtracting the binding energy with zeroed atomic charges from the 
original binding energy with all initial charges. 
 
Free energy of binding calculations 
 
A free energy of binding (∆Gbind) for peptide•DNA systems was computed by considering 
electrostatics (∆Gelec), van der Waals interactions (∆Gvdw) and a cavitation penalty (∆GSASA), as 
done in previous MM-PBSA based approaches [35]. ∆Gelec was calculated using the linearized 
Poisson Boltzmann equation using the software and approach described above. ∆Gvdw was 
computed from the AMBER03 force field Lennard-Jones term with a cutoff of 1.0 nm. The 
cavitation penalty (∆GSASA), which is implemented to quantify the hydrophobic effect and 
favorable van der Waals interactions with water, was estimated using solvent accessible surface 
area. The probe radius used to compute the solvent accessible surface was 1.4 Å with a 
proportionality constant of 0.02267 kJ mol-1 Å-2 [36]. Structures from the last 10 ns of 
simulations were used for binding calculations. A rigid binding assumption was used where the 
“unbound” structures were also taken from the frames of the peptide•DNA simulation.   
 
 
Experimental DNA binding measurements 
 
Chemically synthesized wild type and mutant BF2 and DesHDAP1 (Table 1) at >95% purity 
were obtained from NeoScientific (Cambridge, MA) or GenScript (Piscataway, NJ). The dsDNA 
(double-stranded DNA) for this experiment was obtained from IDT (Coralville, IA) (Table 2). A 
fluorescent intercalator displacement (FID) assay was used to experimentally measure the 
relative DNA binding of each peptide [37, 38]. The FID assay, which has been used previously 
to measure relative DNA binding of HDAPs [9, 39], involved loading of thiazole orange (0.55 
μM), an intercalator that fluoresces upon binding double-stranded nucleic acids, in STE buffer 
(10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 8.0) into a quartz cuvette. Fluorescence was 
measured with 509 nm excitation and 527 nm emission and normalized to 0% relative 
fluorescence. Double stranded DNA or RNA in STE buffer (1.1 μM) was then added. The 
solution was equilibrated for 5 minutes followed by measurement of fluorescence normalized to 
100% relative fluorescence. Aliquots of a prepared peptide solution (7.8 x 10 -5 M) were added 
periodically before mixing, with 5 minutes of incubation before subsequent measurements of 
fluorescence. Concentration of peptide required to displace sufficient thiazole orange to reduce 
fluorescence to half its initial value, or C50, was determined by a linear curve fit. All fits for data 
included in averaging had R2 > 0.88. The relative DNA binding constants were expressed as the 
reciprocal of C50, or 1/C50. In comparing dsDNA sequences, binding constants for both BF2 and 
DesHDAP1 were measured in at least seven independent experiments, and at least three 
independent measurements were performed for comparisons of peptide variants. 
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Results 
 
Structural sampling in DNA binding simulations of buforin II and DesHDAP1 
 
The initial models of BF2 and DesHDAP1 bound to DNA were based on the sections of histone 
H2A protein that were identical to the peptide sequences in a nucleosome core particle crystal 
structure. All modeling and experiments of BF2 included the F10W mutation to allow for 
quantification in experimental studies and more direct comparison to many previous studies 
using that variant [9, 10, 13, 24, 39, 40]. Clearly, the free peptides have significantly fewer 
structural constraints than the analogous region of the histone structure. Moreover, peptides are 
likely unstructured as they move through the cytosol, opening them up to assume different 
conformations upon nucleic acid binding in bacteria as observed in studies of indolicidin [41]. 
Thus, MD simulations were employed to refine these structures and explore potentially different 
binding orientations for the peptide•DNA complexes. To this end, we performed five 
independent 50 ns simulations starting with different initial velocities for each trajectory.  
 
In order to quantify the change in binding conformation over the course of simulations, we 
measured the RMS deviation of the peptide from its initial conformation in two ways. First, we 
superimposed the peptide with its initial structure in order to determine how much the peptide 
changed from its initial conformation (Fig. 1A and 2A). However, this measurement does not 
give insight into any changes in the positioning of the peptide relative to its bound DNA. Thus, 
we also calculated the RMS deviation of the peptide from its initial position when superimposing 
structures throughout the trajectory to the initial position of the DNA backbone (Fig. 1B and 2B). 
This RMS deviation would reflect diffusion to different binding positions on the DNA and 
changes in the relative orientation of peptide and DNA in addition to changes in the peptide 
structure.   
 
In simulations of BF2, all five simulations generally reached an equilibrated conformation of 
peptide with respect to DNA over the course of the 50 ns trajectories.  Generally, the peptides 
maintained similar conformations in each simulation, with some α-helical residues distorted by 
the central Pro 11 residue (Fig. 1A and 1C). However, despite maintaining the same overall 
peptide conformations, the simulations did show different positions relative to the DNA (Fig 1B 
and 1C). These changes primarily increased the interactions between the helical region and the 
DNA backbone, although the helices assumed somewhat different positions in order to develop 
these increased interactions. 
 
DesHDAP1 peptides also explored a range of peptide conformations relative to the bound DNA 
in simulations (Fig. 2). Notably, the terminal portions of DesHDAP1 were positioned relatively 
far from the DNA background in the histone-based initial structure, and all simulations adjusted 
the system to create additional peptide•DNA contacts. All simulations showed enhanced N-
terminal region interactions, which was reasonable considering the concentration of positive 
charges in that region of the peptide. Notably, one of the simulations showed the peptide entering 
a groove region not explored in the other four trajectories. While the C-terminal helix region 
generally did move towards the peptide, this was less consistent between simulations.  
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Based on these results, it would be impossible to evaluate which of the conformations observed 
best reflect the “true” structure of the BF2•DNA and DesHDAP1•DNA complex. In fact, it is 
likely that the actual bound systems may assume a variety of different orientations, particularly 
considering the significant flexibility of a small peptide, and there are probably other potential 
conformations not sampled in our simulations. Although the 250 ns of simulations reported for 
each system were able to capture a range of conformations, more extended simulations may be 
able to uncover additional binding modes or dynamics that occur on a longer timescale. Previous 
circular dichroism measurements did not show a defined structure for BF2 bound to DNA [42]. 
This would be consistent with a peptide assuming a range of binding conformations, including 
some that are less helical than those observed in our simulations, although the overlap of peptide 
and DNA spectra can make determining peptide conformations from circular dichroism difficult 
in bound peptide•DNA systems [23].  
 
Nonetheless, the different conformations observed in our simulations share several similarities in 
terms of the peptide•DNA interactions described below. These similarities give us increased 
confidence in the predictions based on our models as they are not biased by considering one 
particular conformation. To consider the effect of utilizing longer timescale simulations, we also 
performed three preliminary 100 ns simulations of each peptide with DNA, and these extended 
simulations did not cause any qualitative changes in averaged properties used for subsequent 
analyses of peptide•DNA interactions (data not shown). Thus, all results reported in the 
following sections are averaged over the last 10 ns of the five 50 ns simulations.  
 
 
BF2 and DesHDAP1 do not show specific binding of DNA sequences 
 
Previous work had predicted that BF2 and DesHDAP1 peptides might primarily interact with the 
phosphate groups of DNA [9, 11]. We tested whether this was true for our simulations of BF2 
and DesHDAP1 by measuring the average percentage of hydrogen bonds formed between a 
peptide and DNA that involved the DNA phosphate group (Table 3). While the raw numbers of 
hydrogen bonds between a peptide and DNA fluctuated among the five simulations for each 
peptide, a very large percentage of the interactions involved phosphate groups in all simulations. 
For example, no simulation of BF2 had less than 88.0% of peptide•DNA H-bonds involving 
phosphates, and no DesHDAP1 simulation had less than 72.8% of peptide•DNA H-bonds with 
phosphate groups. Because these phosphate groups are identical for any nucleic acid sequence, 
these results imply that there is likely little to no selectivity for particular DNA sequences. 
Interestingly, there was no clear correlation between the extent of conformational change 
observed over the course of a simulation and significantly increased or decreased DNA 
interactions. 
 
To provide a more direct energetic consideration of the peptide•DNA interactions, we employed 
electrostatic analysis to quantify average peptide•DNA interactions in frames taken over the last 
10 ns of each BF2 and DesHDAP1 simulation. To consider the portion of overall interactions 
involving phosphate groups, we calculated the ratio ΔΔGphos :ΔΔGbases (Table 3). ΔΔGphos is 
essentially the contribution of peptidephosphate group interaction to the overall electrostatics 
binding energy between the peptide and DNA. Similarly, ΔΔGbases is the contribution of 
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peptidebase interaction. The fairly high ratios found for the simulations further support that the 
primary interactions between both peptides and DNA involve phosphate groups.  
 
Our computational analyses suggested that little to no selectivity in base sequence should be 
expected for BF2 and DesHDAP1 binding of DNA, as both peptides interact primarily with the 
phosphate groups of nucleic acids. To experimentally test this observation, a fluorescent 
intercalator displacement (FID) assay was used to measure relative binding constants of BF2 and 
DesHDAP1 bound to one of four different double-stranded DNA sequences (Table 2). The 1/C50, 
which is proportional to the binding constant, was compared for the peptides with each DNA 
strand (Fig. 3). The uncertainty in 1/C50 measurements were overlapping for binding with 
different base sequences, and no significant differences arose in one-way ANOVA analyses of 
these results. Thus, these experiments appear to confirm the predicted lack of sequence 
specificity in the DNA binding for these two peptides.    
 
 
Relative arginine composition of basic residues increases DNA binding 
 
In addition to the phosphate interactions, we also noted an interesting trend when considering 
which peptide residues were primarily involved in mediating interactions with DNA (Fig. 4). As 
one might expect, the cationic Arg and Lys residues formed the majority of H-bond interactions 
in each simulation. In fact, the only neutral residue that formed DNA interactions in all five 
simulations for either peptide was the Thr 7 residue of DesHDAP1, which is flanked on either 
side by cationic residues. However, within cationic residues, Arg residues form notably more 
DNA interactions than Lys, with Arg forming over 85% of the cationic residue•DNA H-bonds in 
both BF2 and DesHDAP1 simulations. While Arg residues are more prevalent in these peptides, 
they are nonetheless overrepresented relative to Lys in terms of direct interactions with DNA. 
This may be due to the ability of the guanidinium group in Arg sidechains to form bidentate 
interactions with the DNA phosphate groups, which cannot occur for the amine in Lys.  
 
This potentially important role for arginine in the DNA interactions of these peptides is 
particularly intriguing in light of a recent study of BF2 and DesHDAP1 variants containing all 
lysine residues replaced by arginine (BF2R and DesHDAP1) or all arginine residues replaced by 
lysine (BF2K and DesHDAP1K) (Table 1). In this study, BF2R and DesHDAP1R showed 
increased activity relative to the wild type peptides while BF2K and DesHDAP1K showed 
decreased activity [24]. In order to test the relative importance of arginine composition on the 
DNA binding we performed additional sets of MD simulations of the all-arginine (BF2R and 
DesHDAP1) and all-lysine (BF2K and DesHDAP1K) peptide variants bound to DNA (Table 1). 
Based on the sampling observed for wild type simulations, we performed five replicate 50 ns 
simulations for each peptide variant.  
 
In these simulations, increased arginine composition did lead to increased DNA interactions for 
both peptides.  Simulations with BF2R and DesHDAP1R formed more peptide•DNA H-bonds 
than those for BF2K and DesHDAP1K, respectively (Fig. 5A). We also performed energetic 
analyses of our simulations in which we computed a ∆Gbind for the different peptide variants with 
DNA including electrostatics, van der Waals interactions and a cavitation penalty. This ∆Gbind 
showed an analogous trend to the H-bonding data, with arginine variants binding more strongly 
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than those with increased lysine composition (Fig. 5B). While the quantitative ∆Gbind values may 
be impacted through our rigid binding assumption, we believe they should appropriately capture 
the trends between arginine and lysine mutations due to the minor effect those mutations have on 
the unbound peptide structures [24]. The decreased interactions with lysine relative to arginine 
appeared to occur consistently regardless of the sequence position of a residue, as shown in 
average number of H-bonds per residue in the simulations (Fig. 5C and 5D).  
 
In order to confirm these results experimentally, we measured the DNA binding of these peptides 
with the FID assay employed above. These results confirmed the increased DNA binding of 
BF2R and DesHDAP1R compared to BF2K and DesHDAP1K (Fig. 6). In both computational 
and experimental results, no significant difference was observed between the wt BF2 and BF2R 
peptides, which was consistent with the relatively modest change of a single residue between 
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Discussion 
 
Past studies have noted that intracellular nucleic acids are a potential target for BF2 and other 
HDAPs, such as DesHDAP1, but have not considered whether these peptides might target 
specific nucleic acid sequences. Here, we have utilized MD simulations to explore potential 
DNA binding conformations for these peptides. Although simulations explored different binding 
conformations, all simulations consistently showed that peptide•DNA interactions primarily 
involved the nucleic acid phosphate groups. Because phosphates are identical for all DNA 
sequences, these simulations predicted little to no base sequence selectivity. This prediction was 
confirmed in peptide•DNA binding experiments. These results are consistent with the relatively 
broad spectrum behavior of BF2 and DesHDAP1, which are both active against a range of 
bacterial strains [8, 10, 12]. It may also be more difficult for bacteria to develop resistance 
mechanisms against these peptides, as they are relatively promiscuous in their DNA targeting. 
Moreover, these observations also imply that the differences in BF2 and DesHDAP1 activity that 
do occur between different strains must be due to factors other than nucleic acid differences 
between strains. Previous work showed that indolicidin does have at least some sequence 
specificity in its binding, although it is also hypothesized to primarily bind through phosphate 
groups [41].  Thus, it will be interesting for future studies to consider whether there are any 
general trends of binding specificity for other AMPs believed to interact with nucleic acids. 
 
Our results also emphasized the particular importance of arginine sidechains in mediating 
peptide•DNA interactions. Both simulations and experimental data showed that both BF2 and 
DesHDAP1 variants with increased compositions of arginine residues bind DNA more strongly 
than those with increased lysine compositions. Recent work from our lab showed increased 
antimicrobial activity of the BF2 and DesHDAP1 variants (BF2R and DesHDAP1R) where all 
cationic residues were replaced with arginine [24]. Similar results have been observed for other 
systems, particularly in the design of antimicrobial peptidomimetics [43-48]. While arginine 
residues can also increase membrane interactions, our results here show that the enhanced 
activity of arginine containing peptides may also be due to their increased ability to target 
nucleic acids. This observation is particularly important for peptide design, as it emphasizes how 
increasing the presence of guanidinium groups may be a particular effective strategy since it has 
the potential to enhance multiple aspects of antimicrobial mechanisms.  
 
Overall, these results support the importance of considering how AMPs interact with both the 
lipid membrane and potential intracellular components, as both interactions can play an 
important role in determining antimicrobial activity. For example, considering membrane 
translocation and DNA binding led to a more complete interpretation how proline mutants affect 
activity of BF2 [39]. Although AMPs are often characterized as primarily killing bacteria by 
either permeabilizing membranes or interacting with an intracellular component, several studies 
have proposed that at least some peptides may function through a combination of these different 
mechanisms [19, 23, 49]. Because of their well-characterized membrane and nucleic acid 
interactions, HDAPs may continue to provide a valuable model system for considering how 
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Tables  
 
Table 1:  Sequences of peptides used in the study.  Residues changed between parent peptides 
and variants are highlighted with boldface and underline.  Note that the F10W variant of BF2 
shown in the table was utilized for all models and experiments in this paper as in many previous 
studies. 
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Table 2:  dsDNA sequences used in experimental binding measurements. The H2A-15 sequence 
is identical to the DNA fragment bound by BF2 in the histone H2A structure used as a template 
for simulations [25] and was used in previous DNA binding measurements with BF2 [9]. 
dsDNA name Sequence 
AC ACA CAC ACA CAC ACA 
CG CGC GCG CGC GCG CGC 
AG AGA GAG AGA GAG AGA 
AT ATA TAT ATA TAT ATA 
H2A-15 AAA TAC ACT TTT GGT 
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Table 3:  Interaction results from MD simulations of BF2 and DesHDAP1 with DNA.   
H-bonding data reports the average percentages of all peptide•DNA hydrogen bonds that 
involved the nucleic acid phosphate groups. ∆∆Gphos:∆∆Gbases is the ratio of the electrostatic free 
energy contributions of the phosphate groups to the electrostatic free energy contributions of the 
nucleic acid bases, as determined from Poisson-Boltzmann electrostatics calculations. All values 
are averaged over structures taken from the last 10 ns of simulations. 
 
 BF2 DesHDAP1 
Simulations % H-bonds to 
phosphate 
∆∆Gphos:∆∆Gbases % H-bonds to 
phosphate 
∆∆Gphos:∆∆Gbases 
1 100.0 23.5 84.9 6.5 
2 100.0 14.8 75.9 9.8 
3 96.3 10.9 98.5 19.4 
4 88.0 10.5 72.8 5.6 
5 97.4 12.9 76.6 6.4 
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Figures 
 
Figure 1:  Structural results from BF2•DNA simulations.  For each part simulations shown as 
different color:  simulation 1 (red); simulation 2 (yellow); simulation 3 (green); simulation 4 
(blue); simulation 5 (purple). A)  RMS deviation of BF2 Cα from the initial peptide structure 
when structures at simulation frames were superimposed with the initial peptide structure. B)  
RMS deviation of BF2 Cα from the initial peptide structure when structures at simulation frames 
were superimposed with the initial DNA backbone structure. C)  Final BF2 structures from each 
simulation and the initial BF2 structure. All structures superimposed on the DNA backbone. 
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Figure 2:  Structural results from DesHDAP1•DNA simulations. For each part simulations 
shown as different color:  simulation 1 (red); simulation 2 (yellow); simulation 3 (green); 
simulation 4 (blue); simulation 5 (purple). A)  RMS deviation of DesHDAP1 Cα from the initial 
peptide structure when structures at simulation frames were superimposed with the initial peptide 
structure. B)  DesHDAP1 deviation of BF2 Cα from the initial peptide structure when structures 
at simulation frames were superimposed with the initial DNA backbone structure. C)  Final 
DesHDAP1 structures from each simulation and the initial DesHDAP1 structure. All structures 
superimposed on the initial DNA backbone. Peptide and DNA are shown as backbone ribbons 
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Figure 3:  Experimentally measured relative binding constants, expressed as 1/C50, for BF2 (A) 
and DesHDAP1 (B) with different double-stranded DNA sequences, as given in Table 1. All data 
reported is averaged from at least seven independent binding experiments with error bars shown 
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Figure 4:  Average number of peptide•DNA H-bonds involving each peptide residue in 
simulations of BF2 (A) and DesHDAP1 (B). Averages for each simulation determined over the 
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Figure 5:  A and B)  Average number of H-bonds (A) and ∆Gbind (B) between BF2 and 
DesHDAP1 wild type (gray), arginine (black) and lysine (white) variants and DNA in MD 
simulations. * denotes p<0.05 and ** denotes p<0.01 for t-test comparisons of arginine and 
lysine variants of a peptide.   C and D) Average number of peptide•DNA H-bonds for each 
cationic residue in simulations of wild type, arginine (black) and lysine (white) simulations of 
BF2 (C) and DesHDAP1 (D). Residue names correspond to the wild type peptides. Averages for 
each simulation determined over the last 10 ns, with the error bars shown as the standard error 
from averaging values from the five simulations. 
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Figure 6:  Experimentally measured relative binding constants, expressed as 1/C50, for BF2 and 
DesHDAP1 wild type (gray), arginine (black) and lysine (white) variants with the H2A-15 DNA 
sequence (Table 1). All data reported is averaged from at least three independent binding 
experiments with error bars shown as standard error. * denotes p<0.05 and ** denotes p<0.01 for 
t-test comparisons of arginine and lysine variants of a peptide. 
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